Binah Capital Group Inc. (BCG) Stock Price

1.07 ▼ -0.03 (-2.73%)
Open: 1.12 Vol: 2.78K Day's range: 1.07 - 1.12 Nov 10, 16:00 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
BCG Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 1.11▼ 1.11▼ 1.11▼ 1.11▼ 1.07▲
MA10 1.12▼ 1.11▼ 1.11▼ 1.09▼ 1.10▼
MA20 1.11▼ 1.11▼ 1.11▼ 1.07▼ 1.27▼
MA50 1.08▲ 1.07▲ 1.08▲ 1.14▼ 1.76▼
MA100 1.09▲ 1.13▼ 1.15▼ 1.30▼ 1.94▼
MA200 1.17▼ 1.24▼ 1.29▼ 1.65▼ N/A    
  5 mins 30 mins Hourly Daily Weekly
MACD -0.005▼ -0.003▼ -0.001▼ 0.009▲ 0.006▲
RSI 48.604▼ 49.200▼ 49.442▼ 46.030▼ 36.249▼
STOCH 21.073     25.926     25.926     34.416     24.190    
WILL %R -85.000▼ -85.000▼ -85.000▼ -83.086▼ -82.857▼
CCI -56.195     -56.344     -71.024     -44.085     -55.479    
Latest Filters Detected On BCG
MA $BCG Price Crossed Below MA(13) Set Alert
MA $BCG Price Crossed Below MA(7) Set Alert
CDL $BCG Engulfing Candlestick Pattern Detected Set Alert
CDL $BCG Marubozu Candlestick Pattern Detected Set Alert
Binah Capital Group Inc. News
ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
Monday, November 09, 2026 04:03 AM
( NASDAQ: IBRX) (“ImmunityBio”) and Rafa Laboratories Ltd. (TASE: RAFA) (“Rafa”) today announced that the Israeli Ministry of Health (MoH) has granted approval for ANKTIVA® (nogapendekin alfa ...
ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial
Monday, November 09, 2026 03:32 AM
( NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced positive results from the final analysis of the primary endpoint in Cohort A of QUILT-2.005 ( NCT02138734), a randomized, ...
ImmunityBio's ANKTIVA plus BCG meets goal in bladder cancer trial
Monday, November 09, 2026 03:31 AM
ImmunityBio, Inc. (NASDAQ: IBRX) announced that its drug combination of ANKTIVA plus BCG met the primary efficacy endpoint in a randomized, controlled registrational trial for BCG-naïve ...
BCG historical stock data
date open high low close volume
10/11/26 1.12 1.12 1.07 1.07 2,784
09/11/26 1.10 1.135 1.0871 1.10 6,135
06/11/26 1.13 1.15 1.09 1.11 6,239
05/11/26 1.21 1.21 1.06 1.10 16,277
04/11/26 1.11 1.18 1.11 1.16 11,600
03/11/26 1.06 1.08 1.06 1.06 4,556
02/11/26 1.08 1.125 1.06 1.09 28,079
30/10/26 1.11 1.1484 1.0601 1.08 16,737
29/10/26 1.07 1.17 1.07 1.08 13,474
28/10/26 1.06 1.0879 1.0501 1.0509 4,430
Quote Details
52wk Low:0.95
52wk High:3.44
Vol:2.78K
Avg Vol(3m):314.6K
1Y Chng:-64.21%
1M Chng:-4.46%
Add to Watch List
More Information
Index US Composite
Market Cap. 18.77M